1–6 of 6 results for Complement inhibition
Progression of Geographic Atrophy in Patients Receiving Both Anti-VEGF and Pegcetacoplan Injections
Sean David Adrean, MD, FAAO, FASRS
Annual Meeting Talks
2025
Complement Inhibition Treatment for Geographic Atrophy in Eyes With Exudative AMD
Josh Wallsh
Baseline Characteristics in the Phase 2 GOLDEN Study of IONIS-FB-LRx, an Investigational Antisense Oligonucleotide Designed to Treat AMD-Associated Geographic Atrophy
Glenn J. Jaffe, MD
2022
Beyond Complement: A Novel FAS Inhibition Approach for Neuroprotection in GA
Vaidehi S. Dedania, MD
Updates from the Field
2024
Evaluating ANX007, a Novel C1q Inhibitor, in the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration: The ARCHER Study
Nancy M. Holekamp, MD, FASRS
2021
Episode 157: March Retinal Physician Review with Dr. Shriji Patel including discussion of complement inhibition for AMD, faricimab, brolucizimab, and prefilled syringes for injectable medications
Jayanth Sridhar, MD
Member Podcasts
2018